Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 1 Date: 22 Sep 2023
Reviewer:  Jean-Pierre Zarski
Reviewer's report:
This study reports value suppression tumorigenicity soluble 2 as non-invasive marker in chronic
hepatite C, in comparison with scores Fibroscan, APRI and FIB-4. Unfortunately, only 164
patients were included, which is highly insufficient after eliminating many patients for whom we
have no comparative data. In addition, liver biopsy was not available as a marker for comparison.
Finally, the FIB-4 and the APRI are not the best markers of the fibrose (use the Fibrotest, the
Fibrometer or the Hepascore). Nor do we know the criteria for good-quality elastometry. Results
are not very good, particularly for the diagnosis of severe fibrosis (F3) or cirrhosis.
Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 1 Date: 22 Sep 2023
Reviewer:  Jean-Pierre Zarski
Reviewer's report:
This study reports value suppression tumorigenicity soluble 2 as non-invasive marker in chronic
hepatite C, in comparison with scores Fibroscan, APRI and FIB-4. Unfortunately, only 164
patients were included, which is highly insufficient after eliminating many patients for whom we
have no comparative data. In addition, liver biopsy was not available as a marker for comparison.
Finally, the FIB-4 and the APRI are not the best markers of the fibrose (use the Fibrotest, the
Fibrometer or the Hepascore). Nor do we know the criteria for good-quality elastometry. Results
are not very good, particularly for the diagnosis of severe fibrosis (F3) or cirrhosis.
Please review this paper.
user
Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 1 Date: 22 Sep 2023
Reviewer:  Jean-Pierre Zarski
Reviewer's report:
This study reports value suppression tumorigenicity soluble 2 as non-invasive marker in chronic
hepatite C, in comparison with scores Fibroscan, APRI and FIB-4. Unfortunately, only 164
patients were included, which is highly insufficient after eliminating many patients for whom we
have no comparative data. In addition, liver biopsy was not available as a marker for comparison.
Finally, the FIB-4 and the APRI are not the best markers of the fibrose (use the Fibrotest, the
Fibrometer or the Hepascore). Nor do we know the criteria for good-quality elastometry. Results
are not very good, particularly for the diagnosis of severe fibrosis (F3) or cirrhosis.
assistant